[go: up one dir, main page]

HRP20110086T1 - Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti - Google Patents

Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti Download PDF

Info

Publication number
HRP20110086T1
HRP20110086T1 HR20110086T HRP20110086T HRP20110086T1 HR P20110086 T1 HRP20110086 T1 HR P20110086T1 HR 20110086 T HR20110086 T HR 20110086T HR P20110086 T HRP20110086 T HR P20110086T HR P20110086 T1 HRP20110086 T1 HR P20110086T1
Authority
HR
Croatia
Prior art keywords
docosahexaenoic acid
treatment
acid ester
prevention
pharmaceutical preparation
Prior art date
Application number
HR20110086T
Other languages
English (en)
Croatian (hr)
Inventor
Brune Fr�d�rique
Delhon Andr�
Gardette Jean
Fran�ois Patoiseau Jean
Marty Alain
Severac Etienne
Original Assignee
Pierre Fabre M�dicament S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110086(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre M�dicament S.A. filed Critical Pierre Fabre M�dicament S.A.
Publication of HRP20110086T1 publication Critical patent/HRP20110086T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20110086T 2006-06-23 2007-06-22 Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti HRP20110086T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (en) 2006-06-23 2007-06-22 Dha esters and use thereof in treatment and prevention of cardiovascular disease

Publications (1)

Publication Number Publication Date
HRP20110086T1 true HRP20110086T1 (hr) 2011-03-31

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110086T HRP20110086T1 (hr) 2006-06-23 2007-06-22 Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti

Country Status (38)

Country Link
US (2) US8034377B2 (de)
EP (1) EP2034999B9 (de)
JP (1) JP5053372B2 (de)
KR (1) KR101380128B1 (de)
CN (1) CN101472590A (de)
AR (1) AR061622A1 (de)
AT (1) ATE489091T1 (de)
AU (1) AU2007262958B2 (de)
BR (1) BRPI0713725A2 (de)
CA (1) CA2655570C (de)
CL (1) CL2010001123A1 (de)
CO (1) CO6150156A2 (de)
CR (1) CR10507A (de)
DE (1) DE602007010776D1 (de)
DK (1) DK2034999T3 (de)
EC (1) ECSP099039A (de)
ES (1) ES2355611T3 (de)
FR (1) FR2902659A1 (de)
GE (1) GEP20125464B (de)
HN (1) HN2008001771A (de)
HR (1) HRP20110086T1 (de)
IL (1) IL195562A (de)
MA (1) MA30584B1 (de)
MX (1) MX2009000103A (de)
MY (1) MY145985A (de)
NO (1) NO20090334L (de)
NZ (1) NZ573454A (de)
PL (1) PL2034999T3 (de)
PT (1) PT2034999E (de)
RS (1) RS51629B (de)
RU (1) RU2451672C2 (de)
SA (1) SA07280345B1 (de)
SI (1) SI2034999T1 (de)
TN (1) TNSN08527A1 (de)
TW (1) TWI389888B (de)
UA (1) UA96156C2 (de)
WO (1) WO2007147899A2 (de)
ZA (1) ZA200900334B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
KR20130098279A (ko) 2010-06-18 2013-09-04 엑스바이오테크, 인크. 관절염 치료
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
MX388939B (es) 2010-08-23 2025-03-20 Xbiotech Inc Anticuerpo anti-il-1a para usarse en el tratamiento de cáncer metastásico.
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
WO2018150265A1 (en) 2017-02-16 2018-08-23 Xbiotech, Inc. Treatment of hidradenitis suppurativa
CA3052206A1 (en) * 2017-02-20 2018-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (de) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
EP0125252A1 (de) 1982-11-16 1984-11-21 MOTSCHAN, Georges Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US6015821A (en) 1995-05-01 2000-01-18 Horrobin; David Frederick Nicotinic acid esters and pharmaceutical compositions containing them
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
EP1157692B1 (de) 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Fettsäure enthaltende pharmazeutische Zusammensetzung die wenigstens 80 Gew. % EPA und DHA enthält
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
EP1466597A1 (de) * 2003-04-07 2004-10-13 Clinigenetics Verwendung von dha-Esteren in der Behandlung kardiovasculärer Krankheiten
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
EP1617734A1 (de) 2003-04-17 2006-01-25 Boehringer Ingelheim International GmbH Multivitamin- und mineralstoffergänzung für schwangere

Also Published As

Publication number Publication date
FR2902659A1 (fr) 2007-12-28
AU2007262958A1 (en) 2007-12-27
ECSP099039A (es) 2009-02-27
GEP20125464B (en) 2012-04-10
PT2034999E (pt) 2011-01-19
BRPI0713725A2 (pt) 2012-10-30
MX2009000103A (es) 2009-01-23
WO2007147899A2 (en) 2007-12-27
EP2034999B1 (de) 2010-11-24
NO20090334L (no) 2009-03-04
IL195562A0 (en) 2009-09-01
CL2010001123A1 (es) 2011-03-25
EP2034999A2 (de) 2009-03-18
TWI389888B (zh) 2013-03-21
US20110237613A1 (en) 2011-09-29
RS51629B (en) 2011-08-31
HN2008001771A (es) 2011-01-24
JP5053372B2 (ja) 2012-10-17
US20090312354A1 (en) 2009-12-17
CR10507A (es) 2009-02-05
IL195562A (en) 2012-06-28
SA07280345B1 (ar) 2011-01-15
KR101380128B1 (ko) 2014-04-11
WO2007147899B1 (en) 2008-05-02
CO6150156A2 (es) 2010-04-20
WO2007147899A3 (en) 2008-03-13
AR061622A1 (es) 2008-09-10
RU2008152248A (ru) 2010-07-27
KR20090024794A (ko) 2009-03-09
ES2355611T3 (es) 2011-03-29
ZA200900334B (en) 2009-12-30
SI2034999T1 (sl) 2011-02-28
MA30584B1 (fr) 2009-07-01
EP2034999B9 (de) 2011-03-09
TNSN08527A1 (en) 2010-04-14
CN101472590A (zh) 2009-07-01
RU2451672C2 (ru) 2012-05-27
CA2655570A1 (en) 2007-12-27
UA96156C2 (ru) 2011-10-10
DE602007010776D1 (de) 2011-01-05
JP2009544576A (ja) 2009-12-17
US8227479B2 (en) 2012-07-24
US8034377B2 (en) 2011-10-11
CA2655570C (en) 2015-09-08
TW200811108A (en) 2008-03-01
PL2034999T3 (pl) 2011-05-31
NZ573454A (en) 2010-10-29
AU2007262958B2 (en) 2011-10-27
DK2034999T3 (da) 2011-01-24
ATE489091T1 (de) 2010-12-15
MY145985A (en) 2012-05-31

Similar Documents

Publication Publication Date Title
HRP20110086T1 (hr) Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti
JP2009544576A5 (de)
Vasudevan et al. Pharmacological actions of Thespesia populnea relevant to Alzheimer's disease
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
RU2020123679A (ru) Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
US11052066B2 (en) Ultrapure tetrahydrocannabinol-11-oic acids
NZ737380A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
NZ596386A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
NZ627238A (en) Stable pharmaceutical composition comprising ethyl eicosapentaenoate
NZ594395A (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
RU2009128179A (ru) Наноэмульсия
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
EP0312697A2 (de) Pharmazeutische Zubereitungen zur Behandlung der Psoriasis, psoriatischen Arthritis, Neurodermitis und Enteritis regionalis Crohn
JP5087280B2 (ja) 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用
BR112014005546A2 (pt) ácidos graxos ômega para tratamento de doenças
US7557089B2 (en) Use of derivatives of succinate esters for the treatment of dementia
HRP20150265T1 (hr) Pantenil-dokosaheksanoat i njegova upotreba za lijeäśenje i sprjeäśavanje kardiovaskularnih bolesti
Nemoto et al. Synthesis of highly water-soluble fibrate derivatives via BGLation
CA1314226C (en) Anti-dementia agent
CN109640974A (zh) 多咖啡酰基奎尼酸的酰胺衍生物、其制备方法和用途
CN104546875B (zh) 三萜皂苷衍生物及其医药用途
KR et al. Effect of polyherbal formulation Rumalaya Forte on adjuvant induced arthritis in rats
CN113929581B (zh) 一种丹参素衍生物丹参素酯及其制备方法与应用
JP7475597B2 (ja) Ｆｇｆ２１産生促進剤
CN102659597A (zh) 萘普生丁香酚酯药用化合物及制备方法